Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19
JAMA · 2023
DOI: 10.1001/jama.2023.1650 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Susanna Naggie und 30 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate COVID-19.
Objective
To evaluate the effectiveness of ivermectin at a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo, for the treatment of early mild to moderate COVID-19. Design, Setting, and Participants The ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines 6 (ACTIV-6) platform randomized clinical trial was designed to evaluate repurposed therapies among outpatients with mild to moderate COVID-19. A total of 1432 participants older than 30 years with confirmed COVID-19 experiencing at least 2 symptoms of acute infection for less than or equal to 7 days were enrolled at 93 sites in the US from February 16, 2022, through July 22, 2022, with follow-up data through November 10, 2022.
Interventions
Participants were randomly assigned to receive ivermectin, with a maximum targeted dose of 600 μg/kg (n = 708) daily, or placebo (n = 724) for 6 days. Main Outcomes and Measures The primary outcome was time to sustained recovery, defined as at least 3 consecutive days without symptoms. The 7 secondary outcomes included a composite of hospitalization, death, or urgent/emergent care utilization by day 28.
Results
Among 1432 randomized participants who received study medication or placebo, the median (IQR) age was 48 (38-58) years, 854 (59.6%) were women, and 1188 (83.1%) reported receiving at least 2 SARS-CoV-2 vaccine doses. The median (IQR) time to sustained recovery was 11 (11-12) days in the ivermectin group and 12 (11-12) days in the placebo group. The hazard ratio for improvement in time to recovery was 1.02 (95% credible interval, 0.92-1.12; P value for efficacy = .65). Among those receiving ivermectin, 39 (5.5%) were hospitalized, died, or had urgent or emergency care visits compared with 42 (5.8%) receiving placebo (hazard ratio, 0.97 [95% credible interval, 0.60-1.45]; P = .55). In the ivermectin group, 1 participant died and 6 were hospitalized (1.0%); 2 participants (0.3%) were hospitalized in the placebo group and there were no deaths. Adverse events were uncommon in both groups. Conclusions and Relevance Among outpatients with mild to moderate COVID-19, treatment with ivermectin, with a maximum targeted dose of 600 μg/kg daily for 6 days, compared with placebo did not improve time to sustained recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04885530
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
- Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis.
- Vanderbilt University Medical Center, Nashville, Tennessee.
- School of Data Science, University of Virginia, Charlottesville.
- Clinical Trials Center of Middle Tennessee, Franklin.
Förderung
- NCATS NIH HHS
Zitieren
APA
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Slandzicki, A. J., Lim, S. C., Cohen, J., Kavtaradze, D., Amon, A. P., Gabriel, A., Gentile, N., Felker, G. M., Jayaweera, D., McCarthy, M. W., Sulkowski, M., Rothman, R. L., Wilson, S., DeLong, A., Remaly, A., …, & Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators (2023). Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19. JAMA. https://doi.org/10.1001/jama.2023.1650
Vancouver
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Slandzicki AJ, Lim SC, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19. JAMA. 2023. doi:10.1001/jama.2023.1650
BibTeX
@article{Naggie2023,
author = {Naggie, Susanna and Boulware, David R and Lindsell, Christopher J and Stewart, Thomas G and Slandzicki, Alex J and Lim, Stephen C and Cohen, Jonathan and Kavtaradze, David and Amon, Arch P and Gabriel, Ahab and Gentile, Nina and Felker, G Michael and Jayaweera, Dushyantha and McCarthy, Matthew W and Sulkowski, Mark and Rothman, Russell L and Wilson, Sybil and DeLong, Allison and Remaly, April and Wilder, Rhonda and Collins, Sean and Dunsmore, Sarah E and Adam, Stacey J and Thicklin, Florence and Hanna, George J and Ginde, Adit A and Castro, Mario and McTigue, Kathleen and Shenkman, Elizabeth and Hernandez, Adrian F and Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators, Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators},
title = {Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.1650}
}
EUVIMED